FOLD
Amicus Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FOLD
Amicus Therapeutics, Inc.
A biotech company that develops small molecule drugs to treat Fabry, Gaucher and Pompe diseases
Biological Technology
02/04/2002
05/31/2007
NASDAQ Stock Exchange
499
12-31
Common stock
47 Hulfish Street, Princeton, NJ 08542
--
Amicus Therapeutics, Inc., was incorporated under the laws of the State of Delaware on February 4, 2002. The company is a global, patient-centric biotechnology company focused on discovering, developing and delivering new drugs for rare diseases. The company seeks to provide the highest quality therapies that have the potential to phase out current therapies, provide significant benefits to patients, and become first class or first class. The two therapies the company has marketed are Galafold, the first oral monotherapy for Fabry disease patients with compliant gene variants, and Pombiliti + Opfolda, a novel therapy designed to increase active enzyme uptake in key disease-related tissues in adults with late-onset Pompe disease.
Earnings Call
Q1/2025
Estimate EPS0.08
Actual EPS0.03
Estimate Revenue136.35M
Actual Revenue125.20M
Amicus Therapeutics Q1 2025: Unraveling Contradictions on VPAG Rebate, Patient Starts, and Market Strategy
May 02,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.02
Actual EPS0.01
Estimate Revenue146.68M
Actual Revenue154.69M
Amicus Therapeutics Q2 2025: Unraveling Contradictions in Revenue Impact, Trial Designs, and Market Dynamics
Jul 31,2025 03:23
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
FOLD has released its 2025 Q3 earnings. EPS was reported at 0.06, versus the expected 0.12, missing expectations. The chart below visualizes how FOLD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FOLD has released its 2025 Q3 earnings report, with revenue of 169.06M, reflecting a YoY change of 19.46%, and net profit of 17.31M, showing a YoY change of 357.19%. The Sankey diagram below clearly presents FOLD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
